ATRI - Atrion Corporation
| Previous Close | 641.90 |
| Open | 641.60 |
| Bid | 64.30 x 0 |
| Ask | 657.80 x 0 |
| Day's Range | 641.60 - 663.05 |
| 52 Week Range | 516.85 - 694.25 |
| Volume | 15,965 |
| Avg. Volume | 6,217 |
| Market Cap | 1.219B |
| Beta | 0.17 |
| PE Ratio (TTM) | 36.03 |
| EPS (TTM) | 18.26 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | 5.40 (0.86%) |
| Ex-Dividend Date | 2018-09-13 |
| 1y Target Est | 300.00 |
- Simply Wall St.•19 days ago
Can Atrion Corporation’s (NASDAQ:ATRI) ROE Continue To Surpass The Industry Average?
This analysis is intended to introduce important early concepts to people who are starting to invest and want to learn about Return on Equity using a real-life example. Atrion CorporationRead More...
- GlobeNewswire•last month
Atrion Corporation Increases Quarterly Cash Dividend by 13%
ALLEN, Texas, Aug. 14, 2018-- Atrion Corporation today announced an increase in its quarterly cash dividend from $1.20 per share to $1.35 per share. Specifically, the Board of Directors declared a quarterly ...
- Associated Press•2 months ago
Atrion: 2Q Earnings Snapshot
On a per-share basis, the Allen, Texas-based company said it had net income of $4.74. Earnings, adjusted for pretax gains, were $4.70 per share. The medical device maker posted revenue of $38.8 million ...
- GlobeNewswire•2 months ago
Atrion Reports Second Quarter Results
ALLEN, Texas, Aug. 07, 2018-- Atrion Corporation today announced that for the second quarter ended June 30, 2018 revenues totaled $38.8 million compared with $36.2 million for the same period in 2017. ...
- ACCESSWIRE•4 months ago
Blog Exposure - FDA Approved Expanded Indications for TransEnterix's Senhance Surgical System
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want access to our free research report on TransEnterix, Inc. (NYSE: TRXC), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TRXC as the Company's latest news hit the wire. On May 29, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for expanded indications of the Company's Senhance Surgical System for laparoscopic inguinal hernia and laparoscopic cholecystectomy (gallbladder removal) surgery.
- Associated Press•4 months ago
Atrion: 1Q Earnings Snapshot
The Allen, Texas-based company said it had net income of $4.57 per share. Earnings, adjusted for pretax gains, were $4.56 per share. The medical device maker posted revenue of $39.4 million in the period. ...
- Simply Wall St.•5 months ago
Where Atrion Corporation (NASDAQ:ATRI) Stands In Terms Of Earnings Growth Against Its Industry
Assessing Atrion Corporation’s (NASDAQ:ATRI) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed expectations, which isRead More...
- ACCESSWIRE•6 months ago
Free Post Earnings Research Report: Mettler-Toledo’s Quarterly Earnings Increased 13.07%
Stock Monitor: Atrion Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 12, 2018 / Active-Investors.com has just released a free earnings report on Mettler-Toledo International Inc. (NYSE: MTD ) ...
- Simply Wall St.•6 months ago
Atrion Corporation (NASDAQ:ATRI) Delivered A Better ROE Than The Industry, Here’s Why
Atrion Corporation (NASDAQ:ATRI) delivered an ROE of 19.85% over the past 12 months, which is an impressive feat relative to its industry average of 11.26% during the same period. WhileRead More...
- Associated Press•7 months ago
Atrion posts 4Q profit
On a per-share basis, the Allen, Texas-based company said it had net income of $4.66. The medical device maker posted revenue of $34 million in the period. For the year, the company reported profit of ...
- Simply Wall St.•7 months ago
Should You Be Tempted To Buy Atrion Corporation (NASDAQ:ATRI) Because Of Its PE Ratio?
Atrion Corporation (NASDAQ:ATRI) is currently trading at a trailing P/E of 29.4x, which is lower than the industry average of 33.1x. While this makes ATRI appear like a great stockRead More...
- Capital Cube•10 months ago
ETFs with exposure to Atrion Corp. : December 1, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Atrion Corp. Here are 5 ETFs with the largest exposure to ATRI-US. Comparing the performance and risk of Atrion Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Capital Cube•10 months ago
Atrion Corp. : ATRI-US: Dividend Analysis : December 01st, 2017 (record date) : By the numbers : December 1, 2017
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Atrion Corp. with the following peers – Cooper Companies, Inc., STAAR Surgical Company, C. R. Bard, Inc., TearLab Corp., Teleflex Incorporated, Vuzix Corporation and SPY Inc. (COO-US, STAA-US, BCR-US, TEAR-US, TFX-US, VUZI-US and XSPY-US). Atrion Corp.’s dividend yield is 0.67 percent and its dividend payout ... Read more (Read more...)
- Simply Wall St.•10 months ago
Does Atrion Corporation’s (ATRI) 18.4% Earnings Growth Make It An Outperformer?
After reading Atrion Corporation’s (NASDAQ:ATRI) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past and compareRead More...
- Associated Press•10 months ago
Atrion posts 3Q profit
On a per-share basis, the Allen, Texas-based company said it had profit of $4.29. The medical device maker posted revenue of $37.9 million in the period. Atrion shares have increased 28 percent since the ...
